FDA Panel To Consider Wider Use Of Tarceva In Lung Cancer
December 14 2009 - 10:55AM
Dow Jones News
A Food and Drug Administration panel will consider whether the
cancer drug Tarceva should be approved for wider use in patients
with advanced lung cancer.
Tarceva, comarketed by OSI Pharmaceuticals Inc. (OSIP) and
Roche's (ROG.VX) Genentech unit, is currently approved to treat
non-small cell lung cancer after treatment with chemotherapy failed
to stop the spread of the disease.
The companies are seeking FDA approval to use the drug
immediately after chemotherapy as a maintenance treatment in
patients whose disease remained stable after chemotherapy.
An FDA panel of outside medical experts will meet Wednesday to
make recommendations about whether Tarceva should be granted wider
approval. Tarceva is an oral drug that blocks an enzyme involved
with cancer growth.
The companies conducted a study involving 889 patients with
advanced lung cancer who had completed four cycles of chemotherapy
without their disease progressing or getting worse. Half of the
patients were given Tarceva while the other half were given a
placebo or fake treatment. The study showed patients receiving
Tarceva had a median progression-free survival of 12.3 weeks, or
the time before the disease started getting worse, compared with
11.1 weeks for those on placebo.
In a background document prepared for Wednesday's meeting, the
FDA said the study was successful at meeting its main goal.
However, the agency said the main issue for discussion during the
panel meeting is "other available treatment options."
The FDA said Tarceva, and another drug docetaxel, have a median
survival of three months compared to placebo when given to patients
after chemotherapy has failed. Docetaxel is sold as Taxotere by
Sanofi Aventis SA (SNY).
"This raises the question whether treatment with single agent
erlotinib (Tarceva) or docetaxel after progression are better
options than treatment with erlotinib as maintenance," the FDA
said.
In its background document, OSI said Tarceva provides "an
important new therapeutic option" when given immediately after
chemotherapy.
-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294;
jennifer.corbett@dowjones.com
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Apr 2023 to Apr 2024